GeoVax Q3 net loss $5.8M ($0.91/share); BARDA NextGen trial on track; special meeting adjourned

GeoVax Labs, Inc.

Net loss $5.8M for Q3 2024 ($0.91/share) vs $8.4M ($4.75/share) in Q3 2023; nine-month net loss $16.7M ($4.52/share).
Revenue of $2.8M from BARDA/RRPV Project NextGen award (no revenue in prior year period).
Cash $8.6M at Sep 30, 2024, vs $6.5M at Dec 31, 2023.
BARDA Phase 2b trial of GEO-CM04S1 (10,000 patients) preparing for activation; sites confirmed.
Special Meeting adjourned without business due to lack of quorum (30.4% proxy turnout); reconvened Dec 18, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.